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Abstract
The introduction and acceptance of a standard definition for exacerbations of COPD can be helpful
in prompt diagnosis and management of these events. The latest GOLD executive committee
recognised this necessity and it has now included a definition of exacerbation in the guidelines for
COPD which is an important step forward in the management of the disease. This definition is
pragmatic and compromises the different approaches for exacerbation. However, the inclusion of
the "healthcare utilisation" approach (".. may warrant a change in regular medication") in the
definition may introduce in the diagnosis of exacerbation factors related to the access to health
care services which may not be related to the underlying pathophysiologal process which
characterizes exacerbations. It should be also noted that the aetiology of COPD exacerbations has
not yet been included in the current definition. In this respect, the definition does not acknowledge
the fact that many patients with COPD may suffer from additional conditions (i.e. congestive
cardiac failure or pulmonary embolism) that can masquerade as exacerbations but they should not
be considered as causes of them. The authors therefore suggest that an inclusion of the etiologic
factors of COPD exacerbations in the definition. Moreover, COPD exacerbations are
characterized by increased airway and systemic inflammation and significant deterioration in lung
fuction. These fundamental aspects should be accounted in diagnosis/definition of exacerbations.
This could be done by the introduction of a "laboratory" marker in the diagnosis of these acute
events. The authors acknowledge that the use of a test or a biomarker in the diagnosis of
exacerbations meets certain difficulties related to performing lung function tests or to sampling
during exacerbations. However, the introduction of a test that reflects airway or systemic
inflammation in the diagnosis of exacerbations might be another step forward in the management
of COPD.
Commentary article
Chronic Obstructive Pulmonary Disease (COPD) is char-
acterized by exacerbations which are caused mainly by
infections of the tracheobronchial tree or by inhalation of
toxic gases [1]. During an exacerbation airway inflamma-
tion augments and a sustained worsening of patient's con-
dition from the stable state and beyond normal day-to-
day variations is observed. COPD exacerbations are a
major cause of hospital admissions and frequent exacer-
bations are associated with increased mortality and
impaired health-related quality of life [2]. Previous stud-
ies reported also that patients who experience frequently
exacerbations may present an accelerating rate of lung
function decline [3,4]. In this respect, the management of
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exacerbations by prompt diagnosis and effective treat-
ment that reduces exacerbation frequency [5,6], should be
a major goal in COPD.
However, despite the considerable progress in the under-
standing of the pathobiology of exacerbations and in the
evaluation of their consequences, yet, there is no stand-
ardised definition of an exacerbation. The landmark study
of Fletcher and Peto[7] published in seventies used the
definition of "bronchial infections" (chest cold or ill-
nesses during which phlegm production had increased).
Later, the Lung Health Study[8] used the definition of
"physician visits for lower respiratory illness", while in
recent studies such as in the East London Study[3] and in
a study performed in Greece[4], the definition of an exac-
erbation was based on criteria described previously by
Anthonisen [9]. These criteria require either, increase of at
least two major respiratory symptoms (dyspnea, sputum
amount, and sputum purulence) or, increase of one major
symptom in addition to at least one minor symptom
(wheeze, cough, fever, nasal discharge, sore throat), for at
least two consecutive days. Thus, in those previous stud-
ies, definitions were based either on patient reported
symptom changes [3,4] or, on "healthcare utilisation" due
to the worsening of patients condition [10,11]. However,
it is not known which definition has been better.
Both these two types of definition presented certain draw-
backs. Exacerbations definition, based on symptoms and
signs, is limited by the fact that respiratory symptoms and
signs (increased dyspnea, cough, sputum) which are used
to characterize exacerbations, are not specific and can be
also found in other clinical conditions. In this respect,
common colds, respiratory infections or congestive car-
diac failure may mimic an exacerbation in a patient with
underlying COPD [12-14]. In addition, COPD patients
experience chronic symptoms and mild changes in their
baseline symptoms which may be undetected by the phy-
sician while many patients do not report their symptoms
to physicians or they report it with a delay[15,16]. On the
other hand, the "healthcare utilisation" definition (such
as the need for supplementary medications (i.e. oral corti-
costeroids)[10,11], may be related to the access to health
care services (such as the social and financial situation of
the patient) which vary between countries [4,10]. Conse-
quently, the reported average annual rates noted in most
studies on COPD varied approximately between 1 to 3
depending on the definition used[4,10,11,16]. Hence, in
previous recent years there has been much debate about
how exactly an exacerbation should be defined [11,12].
The introduction and acceptance of a standard definition
can be helpful in the clinical management of COPD
patients. First, exacerbations could be detected and treated
promptly. This is important since a delay in starting
appropriate treatment is associated with a delay in the
recovery from an exacerbation [15]. Second, frequent
exacerbators [3,4] who require treatment that reduces
exacerbation frequency could be identified in early stages
of the disease and could be treated appropriately.
The latest GOLD executive committee recognised the
necessity for a standard definition of exacerbations [1].
Although GOLD executive summary in 2001 used a gen-
eral description of exacerbations based on the worsening
of the clinical condition of the patient, avoiding the use a
standard definition [17], GOLD has now included a defi-
nition of exacerbation in the guidelines for COPD [1].
This is an important step forward.
The current definition states that: "an exacerbation of
COPD is defined as an event in the natural course of the
disease characterized by a change in the patient's baseline
dyspnea, cough, and/or sputum that is beyond normal
day-to-day variations, is acute in onset, and may warrant
a change in regular medication in a patient with underly-
ing COPD"[13]. This definition is pragmatic and it is not
in disagreement with previous definitions. Actually, the
current definition compromises the different approaches
for exacerbation. However, the inclusion of the "health-
care utilisation" approach (".. may warrant a change in
regular medication") in the current definition may intro-
duce in the diagnosis of exacerbation factors related to the
access to health care services which may not be related to
the underlying pathophysiologal process which character-
izes exacerbations[14,15].
In addition, it should be noted that the aetiology of
COPD exacerbations has not yet been included in the cur-
rent definition. In this respect, the definition does not
acknowledge the fact that many patients with COPD may
suffer from additional conditions, such as community
acquired pneumonia, congestive cardiac failure or pulmo-
nary embolism that can masquerade as exacerbations but
they should not be considered as causes of COPD exacer-
bations. In these cases the management may be challeng-
ing for physicians and mandatory for the patients. For
example, patients presenting with symptoms of exacerba-
tion may have pulmonary embolism [17] which requires
anticoagulation. However, warfarin (a common oral anti-
coagulative therapeutic agent) interacts with steroids or
with antibiotics which are required for exacerbations
treatment and thus, more intensive monitoring of the
anticoagulative effect is required. Therefore, inclusion of
the etiologic factors of COPD exacerbations in the defini-
tion might improve further the management of these
cases.
Moreover, COPD exacerbations are characterized by
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significant deterioration in lung function [13]. These fun-
damental aspects should be accounted in diagnosis/defi-
nition of exacerbations. This could be done by the
introduction of a "laboratory" marker in the diagnosis of
these acute events. Previous investigations have shown
that lung function is deteriorated during exacerbations
and that these tests can be performed even in patients with
advanced disease [16,21]. On the other hand, there are
several biomarkers in sputum and exhaled breath conden-
sate which are significantly increased during exacerba-
tions, reflecting the underlying airway inflammation. In
addition, recent studies demonstrated that the measure-
ment of non invasive biological markers of systemic
inflammation such as plasma CRP or serum amyloid A
could confirm exacerbations [22,23]. Therefore, the diag-
nostic value of lung function tests or of inflammatory
markers in the differential diagnosis of COPD exacerba-
tions should be further investigated in order to find the
best of them for the diagnosis or the follow up of COPD
exacerbations. We certainly acknowledge that the use of a
test or a biomarker in the diagnosis of exacerbations
requires prospective studies and meets certain difficulties
related to performing lung function tests or to sampling
during exacerbations [21]. However, the introduction of a
diagnostic test that reflects airway or systemic inflamma-
tion in the diagnosis of exacerbations might be another
step forward in the management of exacerbations for
which we are all looking forward.
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